Process Industries
Mitsubishi Chemical Holdings Corp.
In the news
- Toshiba '50%' on its way to recovering trust, chairman says Jul 13, 2020
- Teijin boosts carbon fiber output in Germany Jun 27, 2020
- Japan's sneeze guard makers reap bonanza from pandemic Apr 25, 2020
- Coronavirus puts sumo tournament at risk as Japan hunkers down Feb 27, 2020
- Japan earnings outlook worsens as slump sucks in services Feb 11, 2020 See more articles on Mitsubishi Chemical Holdings Corp.
Business Summary
Mitsubishi Chemical Holdings Corp. engages in the management of its group companies. It operates through the following segments: Functional Products, Chemicals, Industrial Gas, and Healthcare. The Functional Products segment sells electronics, displays, films, environment and life solutions, molding materials, polymers, chemicals, and new energy to domestic and overseas customers. The Chemicals segment markets methyl methacrylate, petrochemicals, and carbon. The Industrial Gas segment offers gas for the steel, chemical, and electronics industries. The Healthcare segment manufactures and sells pharmaceuticals, diagnostic reagents, and clinical testing products. The company was founded on October 3, 2005 and is headquartered in Tokyo, Japan.
Financial Highlights
| Mar 2020 | JPY | USD |
| Revenue | 3,580.51B | 32,931.56M |
| Gross Profit | 987,263M | 9,080.30M |
| Operating income | 186,691M | 1,717.08M |
| Income before tax | 122,003M | 1,122.11M |
| Net income | 37,185M | 342.00M |
| EBITDA | 426,515M | 3,922.85M |
| Diluted EPS | 35.20 | 0.32 |
| Dividends Per Share | 32 | 0.29 |
| Total Assets | 5,132.14B | 47,539.70M |
| Total liabilities | 3,681.32B | 34,100.50M |
| Total equity | 1,170.22B | 10,839.90M |
| Operating cash flow | 452,003M | 4,157.27M |
| Currency in JPY | Currency in USD |
Historical Data
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | |
| Revenue | 3,543.35B | 3,376.05B | 3,724.40B | 3,840.34B | 3,580.51B |
| Gross Profit | 1,015.04B | 1,009.39B | 1,120.06B | 1,074.52B | 987,263M |
| Operating income | 295,965M | 287,903M | 355,745M | 297,750M | 186,691M |
| Income before tax | 238,808M | 241,379M | 344,077M | 284,846M | 122,003M |
| Net income | 125,227M | 153,673M | 211,788M | 167,058M | 37,185M |
| EBITDA | 478,621M | 461,943M | 534,640M | 497,082M | 426,515M |
| Diluted EPS | 35.03 | 105.95 | 136.05 | 110.04 | 35.20 |
| Dividends Per Share | 15 | 20 | 32 | 40 | 32 |
| Total Assets | 4,223.77B | 4,463.54B | 4,701.41B | 5,572.50B | 5,132.14B |
| Total liabilities | 2,627.62B | 2,765.35B | 2,781.92B | 3,546.65B | 3,681.32B |
| Total equity | 972,197M | 1,091.39B | 1,285.75B | 1,377.94B | 1,170.22B |
| Operating cash flow | 299,612M | 396,643M | 397,940M | 415,575M | 452,003M |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | |
| Revenue | 29,507.20M | 31,176.79M | 33,603.94M | 34,630.52M | 32,931.56M |
| Gross Profit | 8,452.80M | 9,321.47M | 10,105.90M | 9,689.62M | 9,080.30M |
| Operating income | 2,464.64M | 2,658.69M | 3,209.75M | 2,684.98M | 1,717.08M |
| Income before tax | 1,988.66M | 2,229.05M | 3,104.47M | 2,568.61M | 1,122.11M |
| Net income | 1,042.82M | 1,419.12M | 1,910.88M | 1,506.45M | 342.00M |
| EBITDA | 3,985.70M | 4,265.89M | 4,823.85M | 4,482.46M | 3,922.85M |
| Diluted EPS | 0.29 | 0.97 | 1.22 | 0.99 | 0.32 |
| Dividends Per Share | 0.12 | 0.18 | 0.28 | 0.36 | 0.29 |
| Total Assets | 37,579.73M | 40,056.95M | 44,206.99M | 50,345.65M | 47,539.70M |
| Total liabilities | 23,378.46M | 24,816.92M | 26,158.19M | 32,042.77M | 34,100.50M |
| Total equity | 8,649.82M | 9,794.47M | 12,089.79M | 12,449.26M | 10,839.90M |
| Operating cash flow | 2,495.01M | 3,662.86M | 3,590.46M | 3,747.47M | 4,157.27M |
Valuation Measures
| Mar 2020 | |
| PER | 16.87 |
| ROA | 0.69% |
| ROE | 2.91% |
| Operating margin | 5.21% |
| Profit margin | 1.03% |
Key executives
- President & Director: Hitoshi Ochi
- CFO, Director & Managing Executive Officer: Hidefumi Date
- Director & Chief Compliance Officer: Ken Fujiwara
- Group Manager-Business Administration Office: Hajime Komori
- Manager-Business Administration: Motohiro Oki
Shareholders
- Mitsubishi Chemical Holdings Corp. (5.5%)
- Meiji Yasuda Life Insurance Co. (4.2%)
- Sumitomo Mitsui Trust Asset Management Co., Ltd. (4.0%)
- Mitsubishi UFJ Trust & Banking Pension Fund (3.8%)
- Nomura Asset Management Co., Ltd. (3.6%)
- Asset Management One Co., Ltd. (3.6%)
- Nippon Life Insurance Co. (2.8%)
- BlackRock Fund Advisors (2.5%)
- The Vanguard Group, Inc. (2.4%)
- Mitsubishi UFJ Financial Group, Inc. (1.8%)
Contact Details
- Website:http://www.mitsubishichem-hd.co.jp
- Address: Palace Building, 1-1-1 Marunochi, Tokyo, 100-8251, Japan
- Phone: +81.3.6748.7200
Related Companies
- Mitsubishi Chemical Hldgs. Restricted Stock Compensation Plan
- MCPP Innovation LLC
- Diamond Edge Ventures, Inc.
- Mitsubishi Chemical Holdings Board Incentive Plan
- Verbatim Corp.
- Mitsubishi Chemical Imaging Corp.
- MEP Technical Center Asia Ltd.
- MCC Group Holdings (UK) Ltd.
- Life Science Institute, Inc.
- Mitsubishi Chemical Holdings Europe GmbH
- AmperVertice Lda.
- Mitsubishi Plastics Agricultural Film Technology Wuxi Co. Ltd.
- Ryoukou Industrial Co. Ltd.
- Mitsubishi Chemical Analysis Co. Ltd.
- Rhombic Corp. (Japan)
- Verbatim Southern Africa
- Mitsubishi Chemical Holdings (Beijing) Co. Ltd.
- Tai Young High Tech Co. Ltd.
- MCC PTA Asia Pacific Pte Ltd.
- Mitsubishi Chemical Holdings America, Inc.
- Advanced Plastics Compounds Singapore Pte Ltd.
- PT Mitsubishi Chemical Indonesia
- Yoshitomi Engineering Ltd.
- Mitsubishi Chemical Hldgs Business Association
- Kaiteki Institute, Inc.
- Mitsubishi Chemical Infonics Pte Ltd.
- Nihon Gosei Sangyo KK
- Ryoju Corp.
- Mitsubishi Chemical Agri, Inc.
- Japan Unipet Co. Ltd.
Competitors
- DuPont de Nemours, Inc.
- Evonik Industries AG
- Sumitomo Chemical Co., Ltd.
- LG Chem Ltd.
- Eastman Chemical Company
- Arkema SA
- Kolon Industries, Inc.
- Covestro AG
- Sinochem International Corporation Class A
- Celanese Corporation
- Kolon Life Science Inc.
- Polyplex (Thailand) Public Co. Ltd.
- Chemocentryx, Inc.
- UFlex Limited
- Adamas Pharmaceuticals, Inc.
- Acorda Therapeutics, Inc.
- Linde plc
- Fuwei Films (Holdings) Co., Ltd.
- Cytokinetics, Incorporated
- Shenzhen Capchem Technology Co., Ltd. Class A
- Tredegar Corporation
- Voyager Therapeutics, Inc.
- FibroGen, Inc.
- Valneva SE
- BiondVax Pharmaceuticals Ltd. Sponsored ADR
- GrafTech International Ltd.
- Green Seal Holding Ltd.
- Axovant Gene Therapies Ltd.
- OCI Partners LP
- Protalix Biotherapeutics, Inc.
Copyright © 2020 FactSet Research Systems Inc. All rights reserved.
Last Updated on 15 Jul, 2020